Latest Governance And Leadership News

Ironbark Capital Limited reported a 17.6% increase in net profit for FY2025, driven by higher investment income and realised gains, alongside a raised fully franked dividend and an extended share buy-back program.

Eildon Capital Group reported a net loss of $5.7 million for FY2025, weighed down by significant one-off impairments, while pivoting to focused real estate investments with a new $20.8 million joint venture in Queensland.

Pacific Current Group Limited reported a 3.3% decline in revenue and a 19% drop in underlying net profit after tax for FY25, alongside a major share buy-back and key portfolio restructurings.

Actinogen Medical reported a $14.7 million net loss for FY25 while progressing its lead drug Xanamem through pivotal Alzheimer’s and depression trials, with interim results expected in January 2026. The company has secured funding through mid-2026 and is preparing for commercialization.

Regis Healthcare delivered a robust FY25 performance with a 14.5% revenue increase and a dramatic turnaround to a $49 million net profit. The company is advancing growth through acquisitions and greenfield developments, positioning itself strongly ahead of upcoming sector reforms.

Adore Beauty Group reported a modest 1.6% revenue increase in FY25 to $198.8 million, while profit before tax fell 56% due to one-off acquisition and restructuring costs. The company’s integration of iKOU and retail expansion underpin a refreshed omni-channel growth strategy.

Ansell Limited reported robust FY25 results, driven by strong organic growth and the successful integration of Kimberly-Clark’s PPE business. The company also advanced its sustainability commitments and navigated tariff challenges with strategic pricing and sourcing.

NOVONIX Limited reports progress scaling its Chattanooga synthetic graphite plant, secures major funding, and benefits from U.S. tariffs on Chinese imports, while narrowing its half-year loss.

Monash IVF Group reported steady FY25 financial results with revenue and EBITDA growth, while managing clinical incidents and a CEO transition. The company outlines cautious FY26 guidance amid industry headwinds.

Accent Group Limited reported a modest revenue increase but a 3.1% decline in net profit for FY25 amid a tough retail environment. The company announced a strategic partnership with Frasers Group to launch Sports Direct in Australia and New Zealand, signaling a new growth avenue.

Cobram Estate Olives Limited (ASX – CBO) delivered a record FY2025 with a 167.8% surge in net profit and doubled US branded sales, underpinning its growth strategy and sustainability commitments.

Arovella Therapeutics reported a 14% reduction in net loss to $7.5 million for FY25, bolstered by a $15 million capital raise to fund its lead iNKT cell therapy program progressing toward a pivotal phase 1 clinical trial.